Market uptake of new antiviral drugs for the treatment of hepatitis C.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Hepatology

• Publication date

  2008-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jhep.2008.04.021PMID 18682313
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HPV infection in Europe.

  2009cited by this paper
• National Institutes of Health Consensus Development Conference Statement: management of hepatitis B.

  2009cited by this paper
• Current therapy for hepatitis C

  2007cited by this paper
• Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C : a systematic review and economic evaluation

  2007cited by this paper
• Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.

  2007cited by this paper
• Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type?

  2007cited by this paper
• Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies.

  2006cited by this paper
• Sexual Dysfunction is Highly Prevalent Among Men with Chronic Hepatitis C Virus Infection and Negatively Impacts Health-Related Quality of Life

  2006cited by this paper
• Variation in Hepatitis C services may lead to inequity of heath-care provision: a survey of the organisation and delivery of services in the United Kingdom

  2006cited by this paper
• Treating viral hepatitis C: efficacy, side effects, and complications

  2006cited by this paper
• Update on chronic hepatitis C.

  2005cited by this paper
• Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries.

  2005cited by this paper
• Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

  2005cited by this paper
• Barriers to the treatment of hepatitis C. Patient, provider, and system factors.

  2005cited by this paper
• Is the FXR the fix for cholesterol gallstone disease?

  2005cited by this paper
• Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment

  2005cited by this paper
• Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

  2004cited by this paper
• Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C

  2004cited by this paper
• Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients

  2004cited by this paper
• Standardtherapie der akuten und chronischen Hepatitis C

  2004cited by this paper
• Histological findings, genotype distribution and percentage of patients fulfilling the treatment criteria among patients with chronic hepatitis C virus infection in a single Swedish centre

  2004cited by this paper
• The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.

  2004cited by this paper
• Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.

  2004cited by this paper
• [Standard treatment of acute and chronic hepatitis C].

  2004cited by this paper
• A DESCRIPTIVE STUDY OF THE RELATIONSHIP BETWEEN MOOD DISORDERS AND HEPATITIS C TREATMENT COMPLIANCE: DOES NURSING PLAY A ROLE?

  2004cited by this paper
• National Institutes of Health Consensus Development Conference Statement Management of Hepatitis C: 2002 June 10-12, 2002

  2003cited by this paper
• Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C

  2003cited by this paper
• Surveillance of screening for hepatitis C through the laboratory network RENA-VHC, France, 2000-2001.

  2003cited by this paper
• Chronic Hepatitis C: Updated Swedish Consensus

  2003influential reference
• Hepatitis C Virus Subtyping by a Core-Envelope 1-Based Reverse Transcriptase PCR Assay with Sequencing and Its Use in Determining Subtype Distribution among Danish Patients

  2003cited by this paper
• Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C

  2003cited by this paper
• A cost‐effectiveness analysis of peginterferon alfa‐2b plus ribavirin for the treatment of naive patients with chronic hepatitis C

  2003cited by this paper
• Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

  2003cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C

  2003cited by this paper
• National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

  2002cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Ribavirin with or without alpha interferon for chronic hepatitis C.

  2002cited by this paper
• Surprisingly Small Effect of Antiviral Treatment in Patients with Hepatitis C

  2002cited by this paper
• Motion - the available treatments for hepatitis C are cost effective: arguments for the motion.

  2002cited by this paper
• Molecular Characterization of a Full Genome Turkish Hepatitis C Virus 1b Isolate (HCV-TR1): A Predominant Viral Form in Turkey

  2002cited by this paper
• [Chronic hepatitis C from the viewpoint of the patients. There are many causes for the quality of life of patients with chronic hepatitis C to be impaired. But there also exist many possibilities to change it].

  2002cited by this paper
• Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials

  2001cited by this paper
• Emerging infectious diseases in Russia, 1990-1999.

  2001cited by this paper
• Prevalence of hepatitis C virus infection in the general population of northern Spain

  2001cited by this paper
• Leukocyte interferon-alpha in the treatment of chronic hepatitis C in Finland.

  2000cited by this paper
• EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement.

  1999cited by this paper
• Chronic hepatitis C in Sweden: genotype distribution over time in different epidemiological settings.

  1999cited by this paper
• An Update on Chronic Hepatitis

  1999cited by this paper
• Hepatitis C transmission and the underreporting of stigmatized behaviors.

  1998cited by this paper
• Hepatitis C genotypes in Finland determined by RFLP.

  1996cited by this paper
• Prevalence of hepatitis C genotypes among patients with chronic hepatitis C in Norway. Construct Group.

  1996cited by this paper
• The distribution of hepatitis C virus genotypes in Turkish patients

  1995cited by this paper
• Resurging infectious diseases in Russia

  1993cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Feasibility of reaching world health organization targets for hepatitis C and the cost‐effectiveness of alternative strategies

  2018cites this paper
• Clinical effectiveness, cost-effectiveness and acceptability of community-based management of chronic hepatitis C: a mixed methods systematic review protocol.

  2017cites this paper
• Treatment of hepatitis C in injecting drug users in the Perth metropolitan area

  2016cites this paper
• Treatment rate and factors related to interferon‐based treatment initiation for chronic hepatitis C in South Korea

  2016influential citation
• Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014).

  2016cites this paper
• Análisis coste-efectividad de sofosbuvir, interferón pegilado y ribavirina en pacientes con hepatitis crónica por virus C: tratamiento precoz en fases iniciales de fibrosis vs. tratamiento tardío en fases avanzadas

  2016cites this paper
• Hepatitis C virus epidemiology and prevention in Polish and Swiss population - similar and contrasting experiences.

  2016cites this paper
• [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].

  2016cites this paper
• Barriers to HCV treatment in the era of triple therapy: a prospective multi‐centred study in clinical practice

  2015cites this paper
• Hepatitis C: a changing epidemic.

  2015cites this paper
• Rate, delay and predictors of hepatitis C treatment in British Columbia.

  2015cites this paper
• Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment.

  2015cites this paper
• Birth year distribution in reported hepatitis C cases in Switzerland.

  2015cites this paper
• Tools and applications for DNA sequencing in the clinical management of viral infectious diseases : examples from HIV-1 and HCV

  2015cites this paper
• Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States

  2015cites this paper
• Conquering C – Going Beyond Cure

  2015cites this paper
• Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.

  2015cites this paper
• Mathematical analysis of hepatitis C model for intravenous drug misusers: Impact of antiviral therapy, abstinence and relapse

  2014cites this paper
• Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011

  2014cites this paper
• Can hepatitis C virus infection be eradicated in people who inject drugs?

  2014cites this paper
• The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era.

  2014cites this paper
• Fracture risk in hepatitis C virus infected persons: results from the DANVIR cohort study.

  2014cites this paper
• Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention

  2014cites this paper
• Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection

  2014cites this paper
• Continued low uptake of treatment for hepatitis C virus infection in a large community‐based cohort of inner city residents

  2014cites this paper
• High HCV treatment uptake in the Swedish HIV/HCV co-infected cohort

  2014cites this paper
• HCV transmission in industrialized countries and resource-constrained areas

  2014cites this paper
• Strategies to manage hepatitis C virus (HCV) disease burden

  2014cites this paper
• Hepatitis C virus treatment: the unyielding chasm between efficacy and effectiveness.

  2014cites this paper
• Impact of new hepatitis C treatments in different regions of the world.

  2014cites this paper
• Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: a modelling approach.

  2014cites this paper
• Primary and secondary prevention of hepatitis C virus among rural appalachian people who use drugs

  2014cites this paper
• Attendance at specialist hepatitis clinics and initiation of antiviral treatment among persons chronically infected with hepatitis C: examining the early impact of Scotland's Hepatitis C Action Plan

  2014cites this paper
• Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study

  2014cites this paper
• Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements.

  2013cites this paper
• HCV burden in Europe and the possible impact of current treatment.

  2013cites this paper
• A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care

  2013cites this paper
• Socioeconomic status in HCV infected patients – risk and prognosis

  2013cites this paper
• Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies.

  2013cites this paper
• Hepatitis C treatment for multimorbid patients with substance use disorder in a primary care-based integrated treatment centre: a retrospective analysis

  2013cites this paper
• Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: Implications for treatment cost‐effectiveness

  2013cites this paper
• Epidemiology and natural history of HCV infection

  2013cites this paper
• Commentary: absolute and relative contraindications to pegylated‐interferon or ribavirin in the US general patient population with chronic hepatitis C

  2013cites this paper
• Antiviral treatment for chronic hepatitis C infection. Prediction of treatment response and side effects

  2013cites this paper
• Global control of hepatitis C: where challenge meets opportunity

  2013cites this paper
• Commentary: absolute and relative contraindications to pegylated‐interferon or ribavirin in the US general patient population with chronic hepatitis C – authors' reply

  2013cites this paper
• Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting.

  2013cites this paper
• Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers

  2012cites this paper
• Liver cancer and non‐Hodgkin lymphoma in hepatitis C virus‐infected patients: Results from the DANVIR cohort study

  2012cites this paper
• Barriers to hepatitis C treatment

  2012cites this paper
• Predicted effects of treatment for HCV infection vary among European countries.

  2012cites this paper
• Tackling hepatitis C in Australia: the third national strategy.

  2012cites this paper
• New challenges in viral hepatitis

  2012cites this paper
• Hepatitis C prevalence in Denmark -an estimate based on multiple national registers

  2012cites this paper
• Improving access to treatment for patients with chronic hepatitis C through outreach

  2012cites this paper
• Interleukin 28B Gene Polymorphism and Association with Chronic Hepatitis C Therapy Results in Latvia

  2012cites this paper
• Highly active anti-hepatitis C therapy: seven lessons from HIV.

  2012cites this paper
• Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense.

  2012cites this paper
• Barriers and facilitators to hepatitis C treatment for people who inject drugs: A qualitative study

  2012cites this paper
• Market uptake of orphan drugs – a European analysis

  2012cites this paper
• Gender differences in hepatitis C seroprevalence and suboptimal vaccination and hepatology services uptake amongst substance misusers

  2012cites this paper
• Barriers to accessing hepatitis C for individuals who have experience with injection drug use and are accessing methadone maintenance treatment

  2012cites this paper
• Clinical drivers in naïve patient eligibility for treatment of chronic hepatitis C

  2012cites this paper
• Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia

  2011cites this paper
• THE HEPATITIS C TREATMENT PIPELINE REPORT

  2011cites this paper
• Phosphatidylcholines as regulators of glucose and lipid homeostasis: Promises and potential risks

  2011cites this paper
• Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis

  2011cites this paper
• Mortality among Patients with Cleared Hepatitis C Virus Infection Compared to the General Population: A Danish Nationwide Cohort Study

  2011cites this paper
• What Is Killing People with Hepatitis C Virus Infection?

  2011cites this paper
• Infiltrating monocytes versus resident kupffer cells: Do alternatively activated macrophages need to be targeted alternatively?

  2011cites this paper
• The prevalence of viral hepatitis C in Latvia: a population-based study.

  2011cites this paper
• Mortality in patients coinfected with HIV and viral hepatitis B and C in Denmark

  2011cites this paper
• Evolution of HCV incidence in drug users in France

  2011cites this paper
• Increased mortality among persons infected with hepatitis C virus.

  2011cites this paper
• The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference *

  2011cites this paper
• Antiviral therapy for hepatitis C: why are so few patients being treated?

  2010cites this paper
• Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study.

  2010cites this paper
• In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials

  2010cites this paper
• Curing hepatitis C with pills: a step toward global control.

  2010cites this paper
• DALYs in Chronic Hepatitis C : A Paneuropean Perspective

  2010cites this paper
• The state of health economics and pharmaceoconomics research in Russia: a systematic review

  2010cites this paper
• Access to peginterferon plus ribavirin therapy for hepatitis C in Romania between 2002-2009.

  2010cites this paper
• The impact of the prevention programme of hepatitis C over more than a decade: the French experience

  2009cites this paper
• Low uptake of treatment for hepatitis C virus infection in a large community‐based study of inner city residents

  2009cites this paper
• Predictors of antiviral treatment initiation in hepatitis C virus‐infected patients: a Danish cohort study

  2009cites this paper
• Hepatitis C treatment for injection drug users: a review of the available evidence.

  2009cites this paper
• Public health impact of antiviral therapy for hepatitis C in the United States

  2009cites this paper
• Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France

  2009cites this paper
• Is there discrimination in access to therapy for HCV patients?

  2008cites this paper